Alpha 2.0
Login Register
» Articles » PMID: 33443490

An EUA for Bamlanivimab - a Monoclonal Antibody for COVID-19

Overview
Journal Med Lett Drugs Ther
Specialty Pharmacology
Date 2021 Jan 14
PMID 33443490
Citations 9
Affiliations
Soon will be listed here.
Citing Articles

Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis.

Amani B, Shabestan R, Rajabkhah K, Amani B Korean J Transplant. 2023; 37(4):277-285.

PMID: 37916433 PMC: 10772269. DOI: 10.4285/kjt.23.0038.

Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?.

Jiang X, Sun L, Hu C, Zheng F, Lyu Z, Shao J Mar Drugs. 2023; 21(9).

PMID: 37755109 PMC: 10532743. DOI: 10.3390/md21090496.

Effect of the Timing of Amubarvimab/Romlusevimab (BRII-196/198) Administration on Progression to Severe Disease in Elderly Patients with COVID-19 Infection: A Retrospective Cohort Study.

Xu Y, Liu Y, Zheng R, Si S, Xi Y, Deng X Intensive Care Res. 2023; :1-9.

PMID: 37360309 PMC: 10240101. DOI: 10.1007/s44231-023-00040-9.

On variants and vaccines: The effectiveness of Covid-19 monoclonal antibody therapy during two distinct periods in the pandemic.

Srinivasan V, Weinstein S, Bhimani A, Clemons N, Dinolfo M, Shin C PLoS One. 2022; 17(12):e0278394.

PMID: 36454767 PMC: 9714735. DOI: 10.1371/journal.pone.0278394.

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.

Peiffer-Smadja N, Bridier-Nahmias A, Ferre V, Charpentier C, Gare M, Rioux C Viruses. 2021; 13(8).

PMID: 34452507 PMC: 8402761. DOI: 10.3390/v13081642.